Previous 10 | Next 10 |
In the wake of a new public listing that has heightened interest in psychedelics, two executives broke down the importance of this development for the Investing News Network (INN). In September, the psychedelics investment story received a boost thanks to the initial public offeri...
Much like cannabis, psychedelics are quickly going mainstream – and fast, most notably psilocybin. In fact, just over the last few months, Denver, Oakland, and Santa Cruz have recently legalized its use. Joining them, Ann Arbor, Michigan lawmakers voted to decriminalize psilocybin mu...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 20, 2020 – Research continues to mount on the health benefits of psychedelic drugs like psilocybin and loosening government restrictions are completely changing the way the world...
MindMed could be a big player in the psychedelic space with two upcoming catalysts. Two major Phase 2 clinical trials involving LSD. One of which reports Q4 2020 has positive anecdotal evidence. Successful acceptance of the NASDAQ up-listing could serve as another major catalyst f...
Five biotechs, two medical device makers, a solar panel mounting manufacturer, and a Chinese retailer are scheduled to raise $2.0 billion in the week ahead. Several companies could join the IPO calendar early in the week, including McAfee and Datto Holding. Street research is expe...
Gainers: Precigen (PGEN) +26%. Medigus (MDGS) +24%. Aclaris Therapeutics (ACRS) +17%. cbdMD (YCBD) +15%. Abeona Therapeutics (ABEO) +12%.Losers: Mallinckrodt (MNK) -18%. GeoVax Labs (GOVX) -13%. AgeX Therapeutics (AGE) -12%. COMPASS Pathways (CMPS) -9%. ThermoGen...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 7, 2020 – Depression, anxiety, post-traumatic stress disorder (PTSD), and other mental illnesses have been prevalent in the US for quite some time, but the coronavirus pandemic h...
U.K.-based COMPASS Pathways' ([[CMPS]] +2.1%) strong U.S. debut (shares up 140% since September 18) is the clearest signal yet that investors are bullish on the prospects of using psychedelics to treat mental health disorders including treatment-resistant depression ((TRD)).Its cand...
Shares of Compass Pathways (NASDAQ: CMPS) were soaring 21.7% as of 12:26 p.m. EDT on Monday. The big jump came after short-seller Citron Research published a report online recommending the mental health company's stock. Citron Research is primarily known for attacking stocks tha...
Fresh IPO COMPASS Pathways ([[CMPS]] +12.0%) is up in early trade on increased volume. Demand has been robust since its September 18 debut. Shares are up almost 150% from its offering price of $17.Today, Citron Research published a bullish report with a $100 price target. Key points...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...